FDA Approves At-Home Use for Teva's Agitation Drug Igalmi
Translated & summarized from Israel Hayom by baba
The FDA has approved Teva Pharmaceuticals' drug Igalmi for at-home use by adults experiencing acute agitation related to schizophrenia or bipolar disorder. This marks the first time such a treatment can be self-administered outside a medical facility. The approval follows a trial demonstrating safety and preliminary efficacy, though with specific usage restrictions. Teva acquired the drug rights shortly before this significant regulatory milestone.
The story in 6 lines · by baba
- The FDA approved Teva's Igalmi for at-home treatment of agitation in schizophrenia and bipolar disorder patients.
- This is the first drug approved for self-administration outside a clinical setting for this condition.
- Igalmi is a thin film placed under the tongue containing the sedative dexmedetomidine.
- A 12-week trial showed no patients stopped the drug due to side effects, with common issues being drowsiness and dry mouth.
- Teva acquired the drug rights on October 27th for $57.5 million upfront, with potential for more.
- The drug can lower blood pressure and slow heart rate, requiring physician oversight and caution with other sedatives.
The U.S. Food and Drug Administration (FDA) has expanded the approved use of Igalmi, a drug now owned by Teva Pharmaceuticals, allowing patients to administer it at home to treat acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder. This marks the first time a medication for this condition is approved for self-administration outside a clinical setting. Igalmi, which contains the sedative dexmedetomidine, is delivered as a thin film placed under the tongue, dissolving at a 120-microgram dose.
Previously, Igalmi received initial FDA approval in April 2022, but only for use under medical supervision. Clinical trials leading to that approval showed a significant reduction in agitation scores compared to a placebo. The recent approval for at-home use is based on the SERENITY At-Home trial, a 12-week study involving 208 patients. The primary outcome of this trial was safety, with no patient discontinuing the medication due to side effects. Common side effects included drowsiness, dry mouth, dizziness, and a tingling sensation in the mouth.
Preliminary data from the developer indicated that approximately half of the agitation episodes treated with Igalmi resolved completely, compared to one-third in the placebo group, though the trial was not primarily designed to prove efficacy. Important restrictions apply, as the drug can lower blood pressure and slow heart rate, necessitating prior cardiac assessment by a physician. Patients are advised not to drive for at least eight hours after administration and to use caution when combining Igalmi with other sedatives or opioids.
Teva acquired the global rights to Igalmi on October 27th from U.S.-based BioXcel for an upfront payment of $57.5 million, with potential additional payments up to $67.5 million. The application for at-home use was submitted before the acquisition, meaning Teva purchased the drug with its significant approval still pending, a gamble that quickly paid off. This acquisition aligns with Teva's strategy to expand its portfolio of innovative central nervous system and mental health medications. The company plans to announce its marketing strategy, including launch timing and pricing, at a later date.
